Enli Liu

Enli Liu is a clinical investigator who contributed to the landmark study of CD19-directed CAR-NK cell therapy from cord blood in patients with relapsed/refractory B-cell lymphoma and CLL at MD Anderson. This study demonstrated high response rates with minimal cytokine release syndrome or neurotoxicity compared to CAR-T cells, establishing CAR-NK as a potentially safer alternative. His work focuses on improving CAR-NK cell expansion, persistence, and anti-tumor activity through optimal cytokine armoring and genetic modifications.